The recent market volatility has been very disappointing and weighed heavily on a number of ASX shares.
One positive is that I believe it has dragged the shares of some quality companies down to very attractive levels.
Two beaten down ASX 200 shares that I would buy are listed below. Here's why I think they could be good value:
Altium Limited (ASX: ALU)
The Altium share price has been caught up in the tech selloff and is down 22% from its high. While this is disappointing for shareholders, I believe it is a buying opportunity for non-shareholders. This is because I'm confident that this electronic design software company has an exceptionally bright future ahead of it.
The key product in its portfolio is Altium Designer, which has exposure to the rapidly growing Internet of Things and artificial intelligence markets. These two markets are underpinning the proliferation of electronic devices globally and look set to drive strong demand for Altium Designer and its newly released cloud-based Altium 365 offering over the coming years. Management is aiming to grow its revenue to US$500 million by 2025-2026. This compares to revenue of US$189 million in FY 2020. Due to the quality of its offering and favourable industry tailwinds, I'm very confident it will get there.
CSL Limited (ASX: CSL)
The CSL share price has fallen just under 18% from its 52-week high. I think this is a buying opportunity for investors that are looking for long term options. This is because I believe the biotherapeutics giant is perfectly positioned to deliver consistently solid earnings growth over the next decade thanks to its CSL Behring and Seqirus businesses.
CSL Behring is the global leader in plasma therapies and the name behind immunoglobulins products such as Privgen and Hizentra. It also owns haemophilia products Idelvion and Afstyla, among others. The Seqirus business is the second-largest player in the influenza vaccines industry. It plans to manufacture COVID-19 vaccines for Australia should they be successfully developed. Both businesses are also investing heavily in research and development activities and have a large number of potentially lucrative therapies and vaccines at various stages of development.
